サポートされていないブラウザが使用されています。
このサイトの一部の機能が正しく機能しない可能性があります。最適なユーザーエクスペリエンスを得るために、このサイトはChrome、Firefox、Safari、またはEdgeで表示してください。

抗体薬物複合体

Antibody-drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drug composed of an antibody linked to a biologically active drug compound.

ADC process flow and Applications

These novel, targeted agents combine the unique, high specificity, properties and anti-tumor activity of monoclonal antibodies (mAbs) that are tumor-specific but not sufficiently cytotoxic, with the potent cell killing activity of cytotoxic small molecule drugs that are too toxic to be used on their own.

Because the process involves the expansion and purification of mAb-based proteins, ADC bioprocessing begins with the same workflow for regular protein therapeutics. After this phase, further steps are taken for ADC development.

 

 

Conjugation ►

 

Drug is chemically linked to the purified antibody
 

 

精製 ►

 

Resin screening
Polish chromatography 
Scale-down validation
Tangential flow filtration
Analytics
 

 

製剤 

 

フィルタースクリーニング
タンジェンシャルフローフィルトレーション
分析

Repligen solutions​​​​​